Article
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.
The Journal of infectious diseases - 1 Jul 2011
Chayama Kazuaki, Hayes C Nelson, Abe Hiromi, Miki Daiki, Ochi Hidenori, Karino Yoshiyasu, Toyota Joji, Nakamura Yusuke, Kamatani Naoyuki, Sezaki Hitomi, Kobayashi Mariko, Akuta Norio, Suzuki Fumitaka, Kumada Hiromitsu
Abstract excerpt
BACKGROUND: Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as anemia and rash, are frequent. METHODS: We assessed efficacy and predictive factors for sustained virological response (SVR) for triple therapy in 94 Japanese patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.